Drugs / TLT003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01515462 | Apr 2010 → Oct 2023 | Wiskott-Aldrich syndrome | Fondazione Telethon | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TLT003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01515462 ↗ |
| Route | Intravenous | “Eligible subjects will receive intravenous (IV) infusion of TLT003 gene therapy” NCT01515462 ↗ |